What Is the Optimal Dose and Schedule for Dasatinib in Chronic Myeloid Leukemia: Two Case Reports and Review of the Literature.

@article{Jamison2016WhatIT,
  title={What Is the Optimal Dose and Schedule for Dasatinib in Chronic Myeloid Leukemia: Two Case Reports and Review of the Literature.},
  author={Caroline Jamison and Debra Mitchell Nelson and Mete Eren and Dron Gauchan and Ryan C. Ramaekers and Max Norvell and Mehmet Sitki Copur},
  journal={Oncology research},
  year={2016},
  volume={23 1},
  pages={
          1-5
        }
}
Efficacy and safety of dasatinib in chronic phase (CP) chronic myelogenous leukemia (CML) patients has been well established. Initially approved dose and schedule of 70 mg twice daily has been changed to 100 mg once daily after demonstration of the same efficacy with less toxicity. Some patients require significant dose reductions to enable continued treatment with dasatinib. Even at a dose of 80 mg once daily, several patients may require further dose reductions due to substantial toxicity… CONTINUE READING
BETA